Migraine - Lots of Experience, But Less Expertise

Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow pharmaceutical companies to more suitably position and differentiate their product.

Scope

A review of diagnosis and classification of migraine including epidemiology in the seven major markets 

Analysis of therapeutic classes- triptans, ergotamines and alternative treatment options. Including product profiles of key drugs within each class 

An assessment of drug delivery options 

Report Highlights

The triptan market is highly crowded, with a perception of little to offer between available treatments. Clear needs are identified, but research shows that these are either not, or incompletely met. 

As with many disorders, novel formulations and delivery systems can provide a product with a differentiator to maintain/improve its status in the market. In addition to this, such devices for migraine can help build key attributes to meet the needs in specific migraine segments. 

Long-term prophylactic management of migraine offers significant commercial opportunity. Such an indication has generally been seen as an add-on, without due consideration given to an assessment of the unique needs of this area

Reasons to Purchase

Benchmark pipeline migraine treatments and currently marketed products and assess future market potential 

Understand how physicians position current therapies 

Identify potential marketing opportunities both with prescribers and consumers 

January 2004 Pages: 113 

Publisher: Datamonitor CNS Central Nervous System 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS_Central_Nervous_System_2004.html#a541